Zenith Drugs Limited (NSE:ZENITHDRUG)
India · Delayed Price · Currency is INR 78.45
-4.80 (-5.77%)
Jul 24, 2024, 1:30 AM IST
Zenith Drugs Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2018 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2018 - 2020 |
Operating Revenue | 1,333 | 1,316 | 1,145 | 916.55 | 734.02 | Upgrade |
Other Revenue | - | -0 | -0 | 0 | 0 | Upgrade |
| 1,333 | 1,316 | 1,145 | 916.55 | 734.02 | Upgrade | |
Revenue Growth (YoY) | 1.29% | 14.93% | 24.95% | 24.87% | -6.22% | Upgrade |
Cost of Revenue | 876.42 | 856.6 | 783.17 | 727.11 | 522.81 | Upgrade |
Gross Profit | 456.78 | 459.6 | 362.02 | 189.44 | 211.21 | Upgrade |
Selling, General & Admin | 79.72 | 66 | 52.17 | 38.44 | 36.42 | Upgrade |
Other Operating Expenses | 235.26 | 213.24 | 210.8 | 82.69 | 104.51 | Upgrade |
Operating Expenses | 344.65 | 292.25 | 276.02 | 134.39 | 153.09 | Upgrade |
Operating Income | 112.13 | 167.35 | 86 | 55.05 | 58.12 | Upgrade |
Interest Expense | -21.83 | -20.01 | -11.48 | -18.18 | -11.46 | Upgrade |
Interest & Investment Income | 19.59 | 10.83 | 1.6 | 5.22 | 0.61 | Upgrade |
Other Non Operating Income (Expenses) | -15.28 | -9.8 | -10.18 | -2.93 | -1.78 | Upgrade |
EBT Excluding Unusual Items | 94.61 | 148.37 | 65.95 | 39.17 | 45.49 | Upgrade |
Gain (Loss) on Sale of Investments | 0.46 | - | - | - | - | Upgrade |
Other Unusual Items | -2.46 | -15.45 | - | 4.27 | 0.53 | Upgrade |
Pretax Income | 92.61 | 132.92 | 66.57 | 44.06 | 46.02 | Upgrade |
Income Tax Expense | 21 | 37.55 | 17.76 | 12.77 | 15.73 | Upgrade |
Earnings From Continuing Operations | 71.61 | 95.37 | 48.8 | 31.29 | 30.29 | Upgrade |
Minority Interest in Earnings | - | - | 0 | 0.1 | - | Upgrade |
Net Income | 71.61 | 95.37 | 48.81 | 31.38 | 30.29 | Upgrade |
Net Income to Common | 71.61 | 95.37 | 48.81 | 31.38 | 30.29 | Upgrade |
Net Income Growth | -24.92% | 95.40% | 55.53% | 3.60% | -10.90% | Upgrade |
Shares Outstanding (Basic) | 17 | 17 | 12 | 12 | 12 | Upgrade |
Shares Outstanding (Diluted) | 17 | 17 | 12 | 12 | 12 | Upgrade |
Shares Change (YoY) | - | 42.91% | - | - | - | Upgrade |
EPS (Basic) | 4.18 | 5.56 | 4.07 | 2.62 | 2.52 | Upgrade |
EPS (Diluted) | 4.18 | 5.56 | 4.07 | 2.62 | 2.52 | Upgrade |
EPS Growth | -24.90% | 36.70% | 55.53% | 3.60% | -10.90% | Upgrade |
Free Cash Flow | -367.74 | -211.7 | -103.43 | -0.89 | -6.72 | Upgrade |
Free Cash Flow Per Share | -21.44 | -12.35 | -8.62 | -0.07 | -0.56 | Upgrade |
Dividend Per Share | - | 0.500 | - | - | - | Upgrade |
Gross Margin | 34.26% | 34.92% | 31.61% | 20.67% | 28.78% | Upgrade |
Operating Margin | 8.41% | 12.71% | 7.51% | 6.01% | 7.92% | Upgrade |
Profit Margin | 5.37% | 7.25% | 4.26% | 3.42% | 4.13% | Upgrade |
Free Cash Flow Margin | -27.58% | -16.08% | -9.03% | -0.10% | -0.92% | Upgrade |
EBITDA | 141.8 | 180.37 | 99.06 | 68.31 | 70.28 | Upgrade |
EBITDA Margin | 10.64% | 13.70% | 8.65% | 7.45% | 9.57% | Upgrade |
D&A For EBITDA | 29.66 | 13.02 | 13.05 | 13.26 | 12.16 | Upgrade |
EBIT | 112.13 | 167.35 | 86 | 55.05 | 58.12 | Upgrade |
EBIT Margin | 8.41% | 12.71% | 7.51% | 6.01% | 7.92% | Upgrade |
Effective Tax Rate | 22.68% | 28.25% | 26.68% | 28.99% | 34.18% | Upgrade |
Revenue as Reported | 1,359 | 1,337 | 1,158 | 926.66 | 735.16 | Upgrade |
Advertising Expenses | 4.97 | 3.8 | 1.85 | 1.26 | 1.84 | Upgrade |
Updated May 29, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.